Back to results
US 6,143,728 AGranted
Guanylhydrazones useful for treating diseases associated with T cell activation
AssigneeThe Picower Institute for Medical Research
InventorsKevin J. Tracey, Pamela Cohen, Michael Bukrinsky, Helena Schmidtmayerova
Life of this patent
Estimating the term…
Abstract
There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection, using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.
Claims7
A method of treating a disorder or disease characterized by T cell activation, comprising administering a compound having the formula:
- ##STR3## wherein:
- X.sub.2 =GhyCH--, GhyCCH.sub.3 -- or H--;
- X.sub.1, X'.sub.1 and X'.sub.2, independently=GhyCH-- or GhyCCH.sub.3 --;
- Z=--NH(CO)NH--, --(C.sub.6 H.sub.4)--, --(C.sub.5 NH.sub.3)-- or --A--(CH.sub.2).sub.n --A--, n=2-10, which is unsubstituted, mono- or di-C-methyl substituted, or a mono- or di-unsaturated derivative thereof;
- and A=independently --NH(CO)--, --(CO)NH--, --NH(CO)NH--, --NH-- or --O-- and salts thereof, with the proviso that the disorder or disease characterized by T cell activation excludes multiple sclerosis and arthritis.
2 more elements
Dependencies are inferred from the claim text.